NICE have published a guidance for Pfizer’s Xalkori drug to treat ROS1-postivie non-small cell lung cancer has been made available via the Cancer drugs fund.
Head of Oncology at Pfizer UK Craig Eagle commented on the news, “The decision to make the drug available is good news for patients in England. We are committed to continuing to work in collaboration withal parties towards a long term solution on how to assess the limited data that’s’ available, and ensure timely routine access to modern cancer medicines now and in the future. ” Read more here.
Published June 1, 2018